Lorlatinib is a potent, brain-penetrant, third-generation ALK/ROS1 TKI. We performed an analysis of CNS and non-CNS progression in patients with pretreated ALK+ NSCLC. Our results indicate that lorlatinib is active in the treatment and prevention of CNS metastases in patients with ALK+ NSCLC, including those who had progressed on crizotinib or second-generation TKIs. READ ARTICLE
Targeted Oncology Volume DOI:10.1007/s11523-020-00702-4
Authors: Bauer, T.M., Shaw, A.T., Johnson, M.L. et al.
